Arcturus Therapeutics posted a third-quarter loss of $0.26 per share, well ahead of the -$0.60 consensus, a 56.7% positive surprise. Revenue of $18.3 million more than doubled the $8.47 million estimate, a 116.0% beat, and rose 6.7% from a year ago. Earnings improved 46.9% year over year as the net loss narrowed to $7.4 million from $13.4 million. Those numbers say less about the business than they appear to. The quarter was flattered by the wind-down of the CSL Seqirus partnership. Meanwhile, the call broadened the platform story while pushing back the two regulatory decisions investors were watching most closely. That is the central tension.

The quality of the beat deserves scrutiny. The $12.0 million CSL termination payment alone accounts for roughly two-thirds of quarterly revenue. Arcturus also recognized its remaining deferred revenue, and the deferred revenue balance fell from $8.2 million at year-end to just $0.4 million. Strip that out and the recurring base looks thin. Grant revenue fell to $1.4 million from $3.0 million a year ago, and second-quarter revenue was only $3.0 million. Cost control was real. R&D dropped to $17.0 million from $23.3 million as LUNAR-COVID and BARDA activity wound down. The operating loss narrowed to $9.2 million. Even so, the narrower loss reflects a one-time receipt more than a structural improvement, and it will not repeat.

The balance sheet makes the same point. Cash slipped to $184.8 million from $191.5 million in the second quarter. That modest decline included the $12 million CSL inflow, so the underlying burn was considerably heavier. Management still guides runway through year-end 2028. However, it now describes that as "over two years" rather than the "over two and a half years" cited last quarter. The end date is unchanged; the remaining cushion is simply shorter.

Operationally, the tone was more expansive, and the science gave management something to be expansive about.

• **ARCT-810:** The September interim Phase 2 data showed fasting ammonia normalized or maintained, including during increased protein intake. Glutamine fell in all participants, with the 0.5 mg/kg dose bringing mean glutamine into the normal range.
• **LUNAR 2.0:** The next-generation delivery platform showed 38-fold greater potency than ARCT-810's key lipid in non-human primates. It underpins ARCT-2601, which is slated to begin Phase 2 dosing in Q1 2027 with top-line data in the second half of 2027.
• **Pipeline expansion:** The company added PKU (IND planned for 2H 2027) and gout programs, closed the myNEO acquisition for AI-driven antigen design, and took back the EU and UK marketing authorizations for KOSTAIVE ahead of planned 2027 commercial activity.
• **ARCT-032 (cystic fibrosis):** Enrollment in Cohort 4 accelerated with new sites in Israel and Turkey. Completion is expected by year-end, with full data in Q2 2027.

Bears have legitimate ammunition in the timelines, however.

• **CF Phase 3 decision:** Management had guided the go/no-go call for Q4 2026 on the prior call. It declined to confirm that timing this quarter, saying the decision may incorporate later Israel/Turkey patients. The release now says only that the decision will come before the Q2 2027 data. Management called a Phase 3 start by end-2027 "a push." That decision matters because it triggers significant Thermo Fisher funding.
• **OTC end-of-Phase 2 meeting:** Once targeted for the second half of 2026, it now follows ARCT-2601 data in late 2027. The pivotal OTC path is effectively extended by roughly a year.
• **Translation risk:** A 38-fold primate potency gain still has to translate to humans, starting with a cohort of only about six patients.
• **Scope:** The new commitments in European vaccine commercialization, oncology optionality, PKU and gout widen the scope just as the runway shortens.

Investor expectations shifted materially before the report. Earnings Whispers sentiment swung from -0.12 to +0.29, moving from mildly negative to clearly positive. Shares closed at $10.87 heading into the release, up 68.0% from the $6.47 open after the August report, and 20.4% above the 200-day moving average. The path was volatile. The stock surged to a 52-week high of $17.96 on September 17, around the ARCT-810 data, then gave back much of that spike and now sits 39.5% below the peak. The market clearly rewarded the OTC data but has since tempered its enthusiasm. The trend readings fit that picture: sequential growth and AVWAP remain negative even as price action has stabilized.

The bottom line is that Arcturus delivered a headline beat built largely on a non-recurring termination payment. The genuine progress lies in the pipeline: encouraging ARCT-810 biomarker data, a potentially more potent LUNAR 2.0 platform, and a clear 2027 data calendar. That progress comes with a cost. The CF Phase 3 decision and the OTC regulatory path have both drifted later, while cash and runway are narrowing. Sentiment and the share price have already priced in a good portion of the scientific optimism. The next leg of the story depends on 2027 clinical readouts, not on quarterly earnings.